AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23320436 — intervention group
Group type: EXPERIMENTAL
Intervention: gemigliptin
Number of subjects: 425
Study 21918474 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 984
Study 21918474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study 19145494 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg
Number of subjects: 24
Study 19145494 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg
Number of subjects: 24
Study 19145494 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 12 mg
Number of subjects: 24
Study 19145494 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg after high-fat breakfast
Number of subjects: 24
Study 19145494 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 poor metabolisers
Number of subjects: 24
Study 19145494 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine (for comparison)
Number of subjects: 24
Study 17760242 — intervention group
Group type: EXPERIMENTAL
Intervention: New fixator group (n=25)
Number of subjects: 50
Study 17760242 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing group (n=25)
Number of subjects: 50
Study 15259543 — intervention group
Group type: EXPERIMENTAL
Intervention: Active desensitizing agent (UltraEZ) applied daily for 14 days prior to whitening for 30 minutes.
Number of subjects: 40
Study 15259543 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same formulation as UltraEZ without desensitizing agents) applied daily for 14 days prior to whitening for 30 minutes.
Number of subjects: 40
Study 11078068 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic perioperative prednisolone treatment
Number of subjects: 95
Study 11078068 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prednisolone treatment)
Number of subjects: 95
Study 8957021 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg
Number of subjects: 11
Study 8957021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1555812 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of hydroxyzine (10 mg)
Number of subjects: 9
Study 1555812 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of buspirone (5 mg)
Number of subjects: 9
Study 1555812 — intervention group
Group type: COMPARATOR
Intervention: Multi-dose of buspirone (5 mg)
Number of subjects: 9
Study 1555812 — intervention group
Group type: COMPARATOR
Intervention: Multi-dose of chlordiazepoxide (5 mg)
Number of subjects: 9
Study 1555812 — intervention group
Group type: COMPARATOR
Intervention: Multi-dose of hydroxyzine (10 mg)
Number of subjects: 9
Study 1555812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1555812 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG analysis
Number of subjects: 9
Study 3894589 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 50 mg/m2 every 21 days (regimen 1)
Number of subjects: 497
Study 3894589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 every 21 days (regimen 2)
Number of subjects: 497
Study 3894589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 20 mg/m2 for five consecutive days repeated every 21 days (regimen 3)
Number of subjects: 497
Study 30977393 — intervention group
Group type: EXPERIMENTAL
Intervention: Eftilagimod alpha (IMP321) plus paclitaxel
Number of subjects: 0
Study 30977393 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus placebo
Number of subjects: 0
Study 29368349 — intervention group
Group type: EXPERIMENTAL
Intervention: Antera 3D
Number of subjects: 26
Study 29368349 — intervention group
Group type: EXPERIMENTAL
Intervention: Large filter of Antera 3D
Number of subjects: 26
Study 29368349 — intervention group
Group type: COMPARATOR
Intervention: DermaTOP
Number of subjects: 26
Study 29368349 — intervention group
Group type: COMPARATOR
Intervention: Parallel-polarized photographs
Number of subjects: 26
Study 27328954 — intervention group
Group type: EXPERIMENTAL
Intervention: Left TRA
Number of subjects: 150
Study 27328954 — intervention group
Group type: COMPARATOR
Intervention: Right TRA
Number of subjects: 150
Study 27328954 — intervention group
Group type: COMPARATOR
Intervention: TFA
Number of subjects: 150
Study 24336385 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-family intervention (MUFI)
Number of subjects: 97
Study 24336385 — intervention group
Group type: COMPARATOR
Intervention: Single-family intervention (SIFI)
Number of subjects: 97
Study 23558369 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca block (30 mL 0.5% ropivacaine)
Number of subjects: 32
Study 23558369 — intervention group
Group type: COMPARATOR
Intervention: Sham block (30 mL 0.9% NaCl)
Number of subjects: 32
Study 19920766 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg daily for 2 weeks)
Number of subjects: 4373
Study 19920766 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo (daily for 2 weeks)
Number of subjects: 4373
Study 18971523 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine 8 mg monotherapy
Number of subjects: 223
Study 18971523 — intervention group
Group type: COMPARATOR
Intervention: Temocapril 2 mg monotherapy
Number of subjects: 223
Study 18971523 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (azelnidipine and temocapril)
Number of subjects: 223
Study 16650580 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 125 mg
Number of subjects: 219
Study 16650580 — intervention group
Group type: COMPARATOR
Intervention: Parecoxib 40 mg
Number of subjects: 219
Study 16650580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 12855059 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful treatments (psychotherapy)
Number of subjects: 242
Study 12855059 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (briefest treatments)
Number of subjects: 242
Study 12855059 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic study of successful treatments
Number of subjects: 242
Study 12855059 — intervention group
Group type: EXPERIMENTAL
Intervention: Effectiveness research
Number of subjects: 242
Study 12855059 — intervention group
Group type: COMPARATOR
Intervention: Efficacy trials
Number of subjects: 242
Study 10999803 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg x 2 daily for 3 months, then 1,000 mg x 2 daily for 3 months)
Number of subjects: 32
Study 10999803 — intervention group
Group type: COMPARATOR
Intervention: Diane Nova (ethinyl estradiol 35 microg-cyproterone acetate 2 mg)
Number of subjects: 32
Study 8791947 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg b.d. plus clarithromycin 500 mg t.d.s. for the first 2 weeks
Number of subjects: 0
Study 8791947 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg b.d. for 4 weeks
Number of subjects: 0
Study 8791947 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg t.d.s. for the first 2 weeks
Number of subjects: 0
Study 8791947 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 0
Study 1281625 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 55
Study 1281625 — intervention group
Group type: COMPARATOR
Intervention: Epidural hydromorphone
Number of subjects: 55
Study 1281625 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine and hydromorphone
Number of subjects: 55
Study 31424649 — intervention group
Group type: EXPERIMENTAL
Intervention: simple intravenous chemotherapy with cisplatin paclitaxel (TP group)
Number of subjects: 80
Study 31424649 — intervention group
Group type: EXPERIMENTAL
Intervention: gene therapy + intravenous chemotherapy with cisplatin+paclitaxel (rAd‐p53 + TP group)
Number of subjects: 80
Study 31424649 — intervention group
Group type: COMPARATOR
Intervention: radical hysterectomy (RH group)
Number of subjects: 80
Study 28540480 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-phasic injection protocol (saline pacer bolus of 10 ml before three-phasic protocol)
Number of subjects: 2445
Study 28540480 — intervention group
Group type: COMPARATOR
Intervention: Three-phasic injection protocol (CM bolus of 85 ml, followed by 40 ml saline/CM mixture, and 30 ml saline chaser)
Number of subjects: 2445
Study 26502235 — intervention group
Group type: COMPARATOR
Intervention: Control group (chlorhexidine and resin‐modified glass ionomer cement)
Number of subjects: 32
Study 26502235 — intervention group
Group type: EXPERIMENTAL
Intervention: LEDTB group (photodynamic antimicrobial chemotherapy with light‐emitting diode and toluidine blue solution and RMGIC)
Number of subjects: 32
Study 26502235 — intervention group
Group type: EXPERIMENTAL
Intervention: LMB group (photodynamic antimicrobial chemotherapy with laser and methylene blue solution and RMGIC)
Number of subjects: 32
Study 23839029 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxycodone (high dose 45 mg/70 kg)
Number of subjects: 12
Study 23839029 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxycodone (low dose 15 mg/70 kg)
Number of subjects: 12
Study 23839029 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine (high dose 135 mg/70 kg)
Number of subjects: 12
Study 23839029 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine (low dose 45 mg/70 kg)
Number of subjects: 12
Study 23839029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23839029 — intervention group
Group type: COMPARATOR
Intervention: Money
Number of subjects: 12
Study 21793378 — intervention group
Group type: EXPERIMENTAL
Intervention: A-M plasma group (A-M-P)
Number of subjects: 24
Study 21793378 — intervention group
Group type: EXPERIMENTAL
Intervention: NA-M plasma group (NA-M-P)
Number of subjects: 24
Study 21793378 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 22025101 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 228
Study 22025101 — intervention group
Group type: COMPARATOR
Intervention: Self-care book
Number of subjects: 228
Study 22025101 — intervention group
Group type: COMPARATOR
Intervention: Conventional stretching exercises
Number of subjects: 228
Study 17401004 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation followed by surgery (arm A)
Number of subjects: 259
Study 17401004 — intervention group
Group type: COMPARATOR
Intervention: Continuation of chemoradiation (arm B)
Number of subjects: 259
Study 16253169 — intervention group
Group type: EXPERIMENTAL
Intervention: Late course conformal radiotherapy combined with chemotherapy
Number of subjects: 96
Study 16253169 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 96
Study 12012943 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy & Vital (health education and low-intensity exercises)
Number of subjects: 50
Study 10215713 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg.kg‐1
Number of subjects: 120
Study 10215713 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 5 mg.kg‐1
Number of subjects: 120
Study 10215713 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg.kg‐1 with Propofol
Number of subjects: 120
Study 10215713 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg.kg‐1 with Thiopentone
Number of subjects: 120
Study 8550649 — intervention group
Group type: EXPERIMENTAL
Intervention: Inexpensive running shoes
Number of subjects: 39
Study 8550649 — intervention group
Group type: COMPARATOR
Intervention: Leather-soled Oxford-style shoes
Number of subjects: 39
Study 8550649 — intervention group
Group type: COMPARATOR
Intervention: Thin socks
Number of subjects: 39
Study 2194032 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 10
Study 2194032 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg
Number of subjects: 10
Study 2194032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 389843 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinonide 0.05% emollient cream
Number of subjects: 240
Study 389843 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone valerate 0.1% cream
Number of subjects: 240
Study 389843 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide 0.1% cream
Number of subjects: 240
Study 30302901 — intervention group
Group type: COMPARATOR
Intervention: Intralesional triamcinolone acetonide (TRA) injection
Number of subjects: 75
Study 30302901 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intralesional injection of TRA and pentoxifylline (PTX)
Number of subjects: 75
Study 30302901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional pentoxifylline (PTX) injection
Number of subjects: 75
Study 27759579 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (600 mg/day)
Number of subjects: 0
Study 27759579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25701560 — intervention group
Group type: EXPERIMENTAL
Intervention: 2+1 group (two-dose prime and boost)
Number of subjects: 390
Study 23599118 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anakinra, 2.5% (n = 30)
Number of subjects: 75
Study 23599118 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anakinra, 5% (n = 15)
Number of subjects: 75
Study 23599118 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (1% carboxymethylcellulose) (n = 30)
Number of subjects: 75
Study 20693429 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose daunorubicin (50 mg/m² daily for 5 days) + cytarabine (100 mg/m² daily for 7 days)
Number of subjects: 1057
Study 20693429 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose idarubicin (12 mg/m² daily for 3 days) + cytarabine (100 mg/m² daily for 7 days)
Number of subjects: 1057
Study 20693429 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose daunorubicin
Number of subjects: 1057
Study 20693429 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose idarubicin
Number of subjects: 1057
Study 19318972 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 679
Study 19318972 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 679
Study 16445701 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin treatment
Number of subjects: 62
Study 16445701 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 15514727 — intervention group
Group type: EXPERIMENTAL
Intervention: Refracterin, 300 mg/day for 3 days
Number of subjects: 0
Study 15514727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11524065 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg
Number of subjects: 6021
Study 11524065 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 80 mg + Warfarin 1 mg
Number of subjects: 6021
Study 9302908 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus irrigation followed by functional endoscopic sinus surgery (FESS)
Number of subjects: 89
Study 9302908 — intervention group
Group type: COMPARATOR
Intervention: Sinus irrigation alone
Number of subjects: 89
Study 8440842 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward order presentation of survival curves
Number of subjects: 166
Study 8440842 — intervention group
Group type: COMPARATOR
Intervention: Backward order presentation of survival curves
Number of subjects: 166
Study 3546420 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% topical ketoconazole cream (once or twice daily)
Number of subjects: 60
Study 31930949 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) applied to one donor site
Number of subjects: 24
Study 31930949 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP)
Number of subjects: 24
Study 27738812 — intervention group
Group type: EXPERIMENTAL
Intervention: Green/roasted coffee blend (35/65), 3 servings/day providing 510.6 mg hydroxycinnamic acids and 121.2 mg caffeine/day for 8 weeks
Number of subjects: 52
Study 27257953 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone 0.1 mg/kg/day in MCT oil
Number of subjects: 15
Study 27257953 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone 0.2 mg/kg/day aqueous solution
Number of subjects: 15
Study 27257953 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone 0.1 mg/kg/day aqueous solution
Number of subjects: 15
Study 27257953 — intervention group
Group type: COMPARATOR
Intervention: Control (no oxandrolone)
Number of subjects: 15
Study 24930327 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum shoe system
Number of subjects: 20
Study 24930327 — intervention group
Group type: COMPARATOR
Intervention: Forefoot unloading shoe
Number of subjects: 20
Study 23768129 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral acupuncture
Number of subjects: 45
Study 23768129 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral acupuncture
Number of subjects: 45
Study 23768129 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 45
Study 20837289 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoelectric alarms with lithium batteries
Number of subjects: 691
Study 20837289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionizing alarms with lithium batteries
Number of subjects: 691
Study 20837289 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoelectric alarms with zinc batteries
Number of subjects: 691
Study 20837289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionizing alarms with zinc batteries
Number of subjects: 691
Study 18392866 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 253
Study 18392866 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 253
Study 15850466 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine, 100 mg, qd, for 12 months
Number of subjects: 78
Study 15850466 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine-interferon (9 MU, t.i.w.) in combination
Number of subjects: 78
Study 12553110 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrolide antibiotics
Number of subjects: 0
Study 12553110 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic treatment)
Number of subjects: 0
Study 10509062 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing flexion test performed by nine examiners
Number of subjects: 9
Study 10509062 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing flexion test performed by the same examiners
Number of subjects: 9
Study 7587975 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg, p.o.)
Number of subjects: 5
Study 7587975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 1974561 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine (10 mg once daily)
Number of subjects: 20
Study 1974561 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 7195931 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard milk‐based formula
Number of subjects: 0
Study 7195931 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard milk‐based formula with iron
Number of subjects: 0
Study 7195931 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy‐based formula with iron
Number of subjects: 0
Study 31097383 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg
Number of subjects: 87
Study 31097383 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 87
Study 29526502 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg or 75/150 mg every two weeks
Number of subjects: 4629
Study 29526502 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or ezetimibe)
Number of subjects: 4629
Study 29526502 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 4629
Study 27655061 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic testing before antibiotic prescribing
Number of subjects: 162
Study 27655061 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical antibiotic use
Number of subjects: 162
Study 27655061 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic use
Number of subjects: 162
Study 24726098 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive therapy (<120/80 mm Hg)
Number of subjects: 123
Study 24726098 — intervention group
Group type: COMPARATOR
Intervention: Standard antihypertensive therapy (Seventh Joint National Committee compliant)
Number of subjects: 123
Study 22608823 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated workplace laboratory for adults with ADHD
Number of subjects: 119
Study 22608823 — intervention group
Group type: COMPARATOR
Intervention: Controls without ADHD
Number of subjects: 119
Study 20922537 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 163
Study 20922537 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 163
Study 18408581 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home care
Number of subjects: 76
Study 18408581 — intervention group
Group type: COMPARATOR
Intervention: Hospital care
Number of subjects: 76
Study 15752954 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 (large artery compliance)
Number of subjects: 30
Study 15752954 — intervention group
Group type: EXPERIMENTAL
Intervention: C2 (small artery compliance)
Number of subjects: 30
Study 15752954 — intervention group
Group type: EXPERIMENTAL
Intervention: SV/PP (stroke volume/pulse pressure)
Number of subjects: 30
Study 15752954 — intervention group
Group type: EXPERIMENTAL
Intervention: SAC (systemic arterial compliance)
Number of subjects: 30
Study 15752954 — intervention group
Group type: EXPERIMENTAL
Intervention: SI (stiffness index)
Number of subjects: 30
Study 15752954 — intervention group
Group type: EXPERIMENTAL
Intervention: AIx (augmentation index)
Number of subjects: 30
Study 15752954 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP (central pulse pressure)
Number of subjects: 30
Study 15752954 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial PP (brachial pulse pressure)
Number of subjects: 30
Study 11751768 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin resistance
Number of subjects: 2586
Study 11751768 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin resistance
Number of subjects: 2586
Study 11751768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate resistance to penicillin
Number of subjects: 2586